Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.

Hsin-Wei FangYi-Hao YenChao-Hung HungJing-Houng WangTsung-Hui HuSheng-Nan LuChien-Hung Chen

Published in: Digestive diseases and sciences (2021)

The HBsAg of 100 IU/mL at the first clinical relapse could predict persistent virological suppression after clinical relapse in patients who discontinued entecavir or TDF therapy.

Keyphrases

antiretroviral therapy
hiv infected
hepatitis b virus
stem cells
mesenchymal stem cells
bone marrow
cell therapy
smoking cessation